This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links.

We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable.

ITM‘s Clinical Trials for GEP-NET Patients


Neuroendocrine tumors are a rare form of cancer and are frequently of gastroenteropancreatic origin (GEP-NETs). GEP-NETs are often asymptomatic and diagnosed at a late stage with metastases and with limited possibility of surgical removal, thus with still high unmet medical need for treatment.


COMPETE and COMPOSE are two phase III clinical trials to evaluate Targeted Radionuclide Therapy with n.c.a. lutetium-177-edotreotide in patients with neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NETs).

Information for patients

Are you interested in learning more about neuroendocrine tumors, Targeted Radionuclide Therapy, or clinical trials investigating Targeted Radionuclide Therapy for GEP-NETs? Access more information, including participating clinical centers, under the following link.

Information for healthcare professionals

Please find more information on the clinical trials and /or patients’ enrollment under the following link.